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Abstract: The term nuchal translucency (NT) is used to describe the accumulation of fluid 
behind the fetal neck visible on ultrasound in the first trimester of pregnancy. In singleton and 
dichorionic twin pregnancies, increased NT thickness is associated with trisomy 21 and other 
aneuploidies, major fetal anomalies (especially congenital heart disease), and genetic syndromes. 
The pathophysiology and significance of increased or discordant NT in monochorionic twin 
pregnancies is more complex and is associated with twin-to-twin transfusion syndrome and 
other pregnancy complications due to monochorionicity. The long-term neurological outcome 
of euploid children without structural anomalies after increased fetal NT seems to be  favorable. 
Proper counseling is essential in the screening process. Special attention should be paid to the 
assessment of NT screening quality control. Even in the era of arising possibilities for non-
invasive fetal karyotype determination from maternal blood, the role of NT screening is far 
from over. The association of this phenomenon with aneuploidies is only one of its utilities in 
modern obstetrics.
Keywords: nuchal translucency, screening, aneuploidy, congenital anomaly, counseling, 
obstetrics
Nuchal translucency – general considerations
The first report of an increased nuchal thickness (nuchal fold) in fetuses with trisomy 
21 during the second trimester was reported almost two decades ago.1 This finding 
is still considered as the most prominent soft marker in the second trimester genetic 
sonogram. With the advanced ultrasound equipment and demand for an earlier screen-
ing for the aneuploidies, the correlate for nuchal fold (nuchal translucency, NT) during 
the first trimester was reported a few years later.2
This novel observation eventually became the basis of a screening procedure that 
combined ultrasound markers and maternal age.3 The ultrasonographic measurement 
of NT was proposed as a screening method of identifying fetuses at risk for various 
abnormalities, especially autosomal trisomies, major structural anomalies, or single 
gene disorders (SGD).
NT is a transient subcutaneous fluid collection at the back of the fetal neck detect-
able by ultrasound at 10 to14 weeks of gestation. It is visible in virtually all fetuses at 
this gestational age which is determined by means of crown-rump length (CRL).2,3
NT thickness increases with advancing gestational age. After 14 weeks of ges-
tation it usually vanishes.2–6 Normal range of NT measurement changes with ges-
tational age and enlarged NT is variably defined in the literature using a fixed cut 
off (2.5, 3.0, or 3.5 mm), a cut off depending on the CRL measurement of the fetus 
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(ninety-fifth or ninety-ninth percentile), or by using multiple 
of median (MoM) approach.7
Nuchal translucency  
measurement technique
The ideal fetal CRL length for the NT measurement is 
between 45 and 84 mm which corresponds to the gestational 
age from 11+0 to 13+6 weeks of pregnancy.6,8 The procedure 
of the NT measurement is the same as that for the measure-
ment of the fetal CRL with an optimal sagittal projection 
(neutral position). Measurement should not be performed 
when the fetus is in extreme flexion or hyperextension. The 
ultrasound calipers are then placed on the skin and soft tissue 
with the fetus occupying at least 75% of the screen image. 
The maximum thickness of the subcutaneous translucency 
between the skin and soft tissues is measured. Special atten-
tion should be given to the distinction between the fetal skin 
and the amniotic sac line, as both structures appear as thin 
membranes.9 It is generally accepted that at least three sepa-
rate measurements should be obtained and the mean value 
of these measurements reported.
The quality of processes and procedures should be con-
tinuously assessed since operator variability is a potential 
problem.10 NT measurements must be accurate in order to 
provide women with reliable screening results. Therefore, 
systematic training, supervision, and continuing audit are 
necessary to ensure high-quality screening programs.
Pathophysiology of increased  
nuchal translucency
Although many theories have been proposed regarding the 
pathophysiology of the increased NT, the exact cause of this 
phenomenon is still unknown. Underdevelopment of the 
lymphatic system or cardiac anomalies causing early heart 
failure have been suggested as etiological factors.11–13
As an example, in most of the fetuses with Turner syn-
drome and increased NT, cardiac and lymphatic abnormalities 
differ significantly from those in other types of aneuploidies 
and genetic disorders such as Noonan syndrome. Although 
the trisomy 16 mouse model provides insight into the lym-
phatic and cardiovascular development (mouse chromosome 
16 contains the genetic information found on human chro-
mosomes 21 and 22), the phenotypic expression of cardiac 
defects seen in this phenotypic variation is not identical to 
those seen in human trisomy 21.12
Other possible etiological factors include altered 
 composition of the extracellular matrix, congenital infec-
tions, musculoskeletal anomalies, and hormonal disorders. 
Whether a distinction should be made between the NT and 
cystic hygroma in the first trimester is still questionable and 
of limited clinical relevance since the management of these 
situations is identical.
Research on increased NT done on human material 
is limited to a small number of fetuses with different 
karyotypes and genetic syndromes. The pathophysiology 
of the increased NT is probably different depending on the 
underlying conditions, thus generalization is not possible. 
Material from affected human pregnancies is difficult to 
obtain for further investigations since pregnancies involv-
ing fetuses with aneuploidy are still terminated in many 
 counties by destructive vacuum aspiration. Even after medical 
termination of pathological pregnancies, fetal tissues are liq-
uid, fixation very challenging, and consequently pathological 
examination of such tiny anatomical structures post-mortem 
is demanding. Additionally, parents with an euploid fetus 
having increased NT in the first trimester usually decide to 
continue the pregnancy and in such cases the mystery of 
increased NT remains unsolved. The etiology of increased 
NT in monochorionic twin pregnancies is more complex due 
to the intertwin vascular anastomoses. This is discussed in 
a separate paragraph.
Increased nuchal translucency  
and aneuploidy risk
When used as a single test, screening by NT measurement 
in the first trimester has a detection rate of approximately 
73%–82% for trisomy 21 at a false positive rate of 5%–8%. 
If the NT thickness ranges from 3.5 to 4.4 mm, the risk of 
a fetal chromosome abnormality is 21%, increasing to 33% 
if the NT is from 4.5 to 5.4 mm, and 50% if the NT is from 
5.5 to 6.4 mm. The risk of aneuploidy is 65% if the NT 
is 6.5 mm.14
A large multicenter study in the United Kingdom on 
trisomy 21 screening in the first trimester of pregnancy was 
performed by using maternal age and NT thickness.15 Almost 
as many cases of other chromosomal defects than trisomy 
21 cases were detected in each group of increased NT.
Also, in the recent large retrospective study the risk of 
aneuploidy if NT was 3.5 to 4.4 mm was 25% and even 76% 
if NT was greater than 6.5mm.16 This study included a large 
number of fetuses (n=679) with only a minimally increased 
NT (ninety-fifth percentile − 3.4 mm). The main finding was 
that even minimal increase in NT thickness was associated 
with adverse pregnancy outcome (17%). The prevalence 
of aneuploidies in this group was as high as 10%. This is 
an important message in counseling, since most fetuses in 
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the large cohorts were in the group of minimally increased 
NT. However, if the karyotype and the second trimester 
ultrasound scan were normal, there was a 97% chance of 
normal outcome, which is in line with the results of other 
large cohorts.17
Although the majority of euploid fetuses with increased 
NT have a favorable outcome, a minority present with 
structural or neurodevelopmental abnormalities or syn-
dromes which are visible or detected in the postnatal period. 
Some of them are a consequence of submicroscopic 
chromosomal abnormalities that are missed if only con-
ventional karyotyping is performed.18 The use and clinical 
utility of  microarray analysis for routine prenatal diagnosis 
is still being investigated. Important and clinically relevant 
 information may be obtained in certain prenatal situations, 
such as in fetuses with structural anomalies or those who 
are stillborn.
Counseling may occasionally be difficult because of the 
uncertain phenotype associated with some array findings, so 
called “variant of unknown significance”.19 Pretest and post-
test counseling are imperative whenever prenatal microarray 
testing is performed.18
Increased nuchal translucency  
and major congenital anomalies
Increased NT is strongly associated with major congenital 
anomalies, most of them easily detectable by ultrasound in 
the second trimester screening. Some of them may be visible 
also in the first trimester. Although congenital diaphragmatic 
hernia, clefts, omphalocele, and body stalk anomalies are 
common in both euploid and aneuploid fetuses with increased 
NT, structural congenital heart defects (CHD) have been 
described as the most common anomaly associated with 
increased NT in large cohorts.16,17,20–22 These are associated 
with high rates of mortality and morbidity, accounting for 
20% of stillbirths and 30% of neonatal deaths. The prevalence 
of major cardiac defects increases by increasing degree of 
NT thickness (between 17/1,000 at NT thickness ninety-fifth 
percentile − 3.4mm and 78/1,000 at NT 3.5 mm).21
CHD is a heterogeneous group of conditions; some of 
them are minor without need for postnatal intervention, 
while others may lead to serious disability. Due to the 
improved rate of prenatal diagnosis and the advances in 
postnatal  cardiac surgery, many of the major CHD can be 
satisfactorily repaired after birth. However, only 5%–10% 
of all major cardiac defects will be detected if a screening 
strategy is based only on maternal history ie, family history 
of CHD, maternal diabetes, fetal extracardiac anomaly, and 
the use of teratogenic drugs (lithium, anti-epileptic drugs). 
These “at-risk” women account for only 2%–5% of the whole 
pregnant population.
Previous research on NT and CHD has not focused 
on defects that would benefit from prenatal detection. In 
a recent meta-analysis, a subgroup of 159 fetuses with 
CHD for which prenatal detection would be beneficial were 
identified antenatally.23 The performance of NT as a screen-
ing test for detecting these defects was assessed. The NT 
measurements were compared with NT measurements in 
29,776 euploid fetuses without CHD from the Serum Urine 
and Ultrasound Screening Study (SURUSS) trial.24 Using 
NT cut off of 1.7 MoM, the estimated detection rate for a 
5% false positive rate was 52%. Authors concluded, that 
screening for CHD of fetuses having NT above 1.7 MoM 
could reasonably identify about half of the cases benefitting 
from prenatal diagnosis. Continuing pregnancies with NT 
measurements of 1.7 MoM or greater could be referred for 
detailed fetal cardiac ultrasound  examination. Women found 
to have affected pregnancies would receive prenatal coun-
seling regarding long-term prognosis of the fetuses with the 
specific cardiac defect. Affected children, particularly cases 
where early intervention has been demonstrated to improve 
prognosis,22 could be delivered at units with suitable neona-
tal expertise. As part of prenatal counseling, termination of 
pregnancy is often discussed with parents, particularly in 
cases where CHD is severe.
Although the second trimester sonogram is a valu-
able tool in prenatal CHD screening, increasing numbers 
of studies suggest high performance in the late f irst 
trimester or even earlier. However, it must be acknowl-
edged that even in  experienced hands some CHD remain 
undetected. An effective strategy for prenatal screening 
includes an early detection, improved antenatal, intrapar-
tum, and postnatal management reducing morbidity for 
survivors.25
Increased nuchal translucency  
and single gene disorders
SGD are caused by individual mutant genes present in one 
or both chromosomes of a pair. They affect up to 2% of 
the population during the entire life span with more than 
5,000 described SGD so far. Since the introduction of the 
NT as screening marker for fetal aneuploidies, the list of 
genetic syndromes presenting with an increased NT is 
rapidly growing. The most frequent syndromes frequently 
 associated with increased NT in the first trimester are 
 Noonan  syndrome, Smith–Lemli–Opitz syndrome, di George 
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syndrome,  achondrogenesis, myotonic dystrophy, and some 
other musculoskeletal disorders.
Most of SGD are relatively rare and are reported in 
large cohorts of fetuses from unselected populations with 
increased NT. Recently, the predictive value of increased 
NT for SDG was assessed in 196 selected pregnancies at 
risk.26 All women were referred because of either maternal 
or paternal history of Mendelian disorder. The mutation was 
previously identified in one of the parents in most cases. In a 
few cases, prenatal diagnosis was carried out because of a risk 
of germinal mosaicism after de novo mutation in an offspring 
affected by a dominant single-gene disorder. Monochorionic 
twin pregnancies were excluded because of the confounding 
effect on an increased NT of both conditions. Chorionic villus 
sampling (CVS) was performed in all pregnancies.
The measurement of fetal NT had no association with 
fetal diagnosis of X-fragile mental retardation syndrome, 
Huntington disease, and Duchenne muscular dystrophy in 
these pregnancies as no differences were found between the 
63 affected and 116 non-affected fetuses. However, increased 
NT was associated with two SGD previously undescribed, 
ie, Hunter syndrome (mucopolysaccharidosis type II) and 
Emery–Dreifuss dystrophy. Alterations of extracellular 
matrix could explain this finding in inherited metabolic 
disorders. Authors concluded that regardless of these asso-
ciations, it is likely that invasive procedures will remain the 
standard approach for pregnancies at high risk of SGD.
Another study used multiple technologies (a DNA chip 
using the APEX technology, quantitative real-time PCR 
(qPCR), microfluidic PCR, and sequencing) to test 310 
mutations across five conditions – Noonan syndrome, con-
genital adrenal hyperplasia, spinal muscular atrophy (SMA), 
diGeorge syndrome, and Smith–Lemli–Opitz syndrome 
in 120 euploid fetuses in order to assess the approach for 
monitoring SGD associated with the increased NT.27 The 
only significant association was found with Noonan syn-
drome while the reported association of the remaining four 
genetic syndromes was weak. As the failure to detect any 
pregnancies affected by four of the five conditions suggests 
that the association of these SGD with increased NT is likely 
to be less than 1 in 100, authors doubt the utility of popula-
tion screening. Noteworthy, they conclude that the anxiety 
of patients generated by the knowledge of increased NT can 
be reduced if the pregnancy is predicted not to be affected 
with the conditions comprising the current panel.
The largest studies published after the year 2000 of struc-
tural anomalies and genetic disorders detected in euploid 
fetuses with increased NT are displayed in Table 1.16,17,28–31
Nuchal translucency screening  
in twin pregnancies
Monozygotic pregnancies represent about 33% of all 
spontaneously-conceived twins, and two thirds of those are 
monochorionic. The risk of any pregnancy complication 
including the most serious such as fetal or neonatal death 
in monochorionic twin pregnancies is substantially higher 
than in dichorionic twins. Intertwin vascular anastomoses 
are present in virtually all monochorionic placentas and 
may potentially lead to acute or chronic imbalances between 
the circulations.32 In the most severe form, this imbalance 
may ultimately lead to sudden fetal death or twin-to-twin 
 transfusion syndrome (TTTS) with subsequent high  mortality 
and morbidity.
Monochorionic placentation is the serious  pregnancy 
abnormality which is far more common than fetal 
malformations. TTTS develops when there is the abnormal 
Table 1 The largest studies published after 2000 reporting outcome of euploid fetuses with increased nuchal translucency in the first 
trimester screening
Study Euploid  
fetuses (n)
NT (mm) Structural  
anomalies
Genetic disorders (including 
neurodevelopmental delay)
Anomalies detected 
after birth
Mangione et al,28 2001 202 3 mm 23/202 (11.4%) 1/201 (0.5%) NR
Souka et al,29 2001 1,320 3.5 mm 162/1,320 (12.3%) 44/1,320 (3.3%) 22/980 (2.2%)
Michailidis and  
economides,30 2001
235 95th percentile 5/235 (2.1%) NR NR
Senat et al,31 2002 89 4 mm 23/89 (25.8%) 4/62 (6.4%) 4/62 (6.5%)
Bilardo et al,17 2007 425 95th percentile 27/425 (6.3%) 23/425 (5.4%) 10/375 (2.7%)
Äyräs et al,16 2013 834 95th percentile 60/834 (7.2%) 14/834 (1.7%) 9/834 (1.1%)
Total 3,105 – 300/2,331 (12.8%) 
Range 2.1%–25.8%
86/2,463 (3.4%) 
Range 0.5%–6.4%
45/2,251 (2.0%) 
Range 1.1%–6.5%
Notes: Adapted from increased nuchal translucency in euploid fetuses—what should we be telling the parents? Bilardo CM, Timmerman e, Pajkrt M, van Maarle M. Prenatal 
Diagnosis. 2010;30(2):93-102. Copyright © 2010 John wiley & Sons, Ltd.32
Abbreviations: NR, not reported; NT, nuchal translucency.
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blood transfusion from the donor twin to the recipient twin in 
cases when the interfetal anastomoses fail to balance the two 
circulations. The early (first trimester) imbalance in the blood 
flow through the intertwin vascular anastomoses may result 
in subtile early cardiac failure of the recipient twin leading 
to the increased NT. If the imbalance is not self-corrected, 
the most common result is early fetal death rather than TTTS 
which occurs later in pregnancy.33,34
Sebire et al35 first described increased NT discordance 
among twins developing TTTS in a retrospective cohort 
of 303 monochorionic pregnancies. This same observation 
was confirmed in a larger cohort of 512 monochorionic 
pregnancies with relatively high predictive value for TTTS.36 
However, the results of another cohort of 135 monochorionic 
pregnancies did not support this observation.37
The assessment of reversed A wave of ductus venosus 
(DV) may give better insight and increase predictive value 
on the development of TTTS in monochorionic twins, 
especially in cases with discordant NT. This limits the use 
of NT as an exclusive screening method for identification 
of those monochorionic pregnancies that are developing 
TTTS and thus would require closer follow-up and possibly 
eventual laser treatment. Additionally, assessment of DV flow 
requires proper ultrasound equipment and high expertise of 
the operator.38,39
The first trimester sonographic screening for aneuploidy 
provides the opportunity to assess potential prognostic factors 
in monochorionic twin pregnancies. If a progressively asym-
metrical vascular pattern develops, then second trimester 
features of TTTS will appear.
In monochorionic diamniotic pregnancies the fre-
quency of an abnormal NT is as high as 15%, without 
epidemiological demonstration of a higher frequency of 
chromosomal  abnormalities compared to singletons and 
dichorionic twins. Monozygotic twin pairs may have discor-
dant karyotypes (heterokaryotypia) which may result from 
a mitotic error arising either before twinning, resulting in 
a mosaic, or after splitting, resulting in the chromosomal 
abnormality in one of the fetuses.32
Unfortunately, there are no data for the distribution of 
NT in trisomy 21 and fetuses with normal karyotype from 
monochorionic pregnancies for the purpose of calculating 
likelihood ratios.32 Additionally, in cases of discordant NTs 
there is no universal agreement which of the two NTs should 
be considered for risk calculations. However, Cuckle and 
Maymon have recently described a method for calculat-
ing fetus-specific Down syndrome risks from a series of 
325 unaffected twins after adjustment for sonographer bias 
using its own NT value as well as that of the co-twin tak-
ing into consideration zygosity, chorionicity, maternal age, 
 ethnical origin, and fetal sex.39
In singleton and dichorionic twin pregnancies, enlarged 
NT (greater than the ninety-fifth percentile) is encountered in 
about 5% of cases. In dichorionic twins, patient specific risks 
for trisomy 21 are calculated for each fetus on the basis of 
maternal age and the fetal NT and detection rate (75%–80%) 
and false positive rate (5% per fetus or 10% per pregnancy) 
is similar to those in singleton pregnancies.40,41 Therefore, 
effective screening and diagnosis of major aneuploidies can 
be achieved in the first trimester, allowing the possibility 
of earlier and therefore safer selective fetocide and thus 
improving the pregnancy outcome in cases where one fetus 
is euploid and the other has either chromosomal abnormality 
or major structural anomaly.42
When screening is done by NT measurement and mater-
nal age, a pregnancy specific risk should be calculated in 
monochorionic twins. In dichorionic twins, a fetus specific 
risk should be calculated.43
Long-term neurodevelopmental  
outcome of euploid children  
from pregnancies with increased  
nuchal translucency
Once increased NT is detected, parents need counseling 
about the expected outcome of the pregnancy.  Chromosomal 
defects can be ruled out by karyotyping. Structural abnor-
malities are usually diagnosed at the second trimester 
ultrasound scan. Without major structural anomalies visible 
on ultrasound, there is a 97%–98% chance of favorable 
outcome.16,17
Neurodevelopmental disorders are impairments of the 
growth and development of the brain or central nervous 
system. A narrower use of the term refers to a disorder of 
brain function that affects emotion, learning ability, self-
control, and memory unfolding later during the growth. 
Neurodevelopmental disorders may manifest as behavioral 
and cognitive problems. Thus, these disorders occur later in 
childhood than structural anomalies. A definitive neurode-
velopmental diagnosis usually requires long follow-up with 
repeat examinations. Several studies have been published 
about the long-term neurodevelopmental outcome of children 
with increased NT.17,31,44–49 The percentage of neurodevelop-
mental disorders has varied between 1.1% and 7.4% in these 
studies. Comparison of the studies is difficult due to small 
study populations and variable NT cutoff levels and methods. 
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According to the most recent publications, the neurological 
outcome of children after increased fetal NT seems to be 
favorable by the age of 24 months.48,49
Management of pregnancies with 
increased nuchal translucency
After detailed anatomy survey, CVS or amniocentesis should 
be offered to all women for karyotyping. Some authors have 
proposed that, in fetuses with enlarged NT and obvious 
structural major anomalies, termination of pregnancy may be 
offered directly to save the cost of karyotyping. This approach 
is not acceptable (unless parents are reluctant to undergo 
karyotyping after counseling) in contemporary perinatal 
practice for several reasons: 1) pregnant women should be 
offered all necessary investigations to clarify the etiology 
of the increased NT; 2) karyotyping is important not only to 
define the recurrence of risk, but also to help parents in the 
decision making process; 3) postmortem karyotyping is not 
always possible and even in experienced laboratories, culture 
failure may be as high as 15%.
In fetuses with grossly enlarged NT, cystic hygroma or 
hydrops, ultrasound should be performed again at 15 weeks to 
ensure fetal viability. In euploid fetuses with continuation of 
pregnancies, third level detailed ultrasound assessment of fetal 
anatomy with special attention to fetal echocardiography should 
be offered around 20 weeks. In cases of any major structural 
anomaly, a multidisciplinary team should be involved in coun-
seling, pregnancy follow-up, timing and organizing delivery in 
the third-level prenatal center with high quality neonatal care. 
Intrauterine treatment should be offered, if possible.
In the case of intrauterine demise, fetal autopsy and other 
investigations to reveal etiology of increased NT should be a 
standard care followed by proper counseling. Psychological 
support to the family should not be ignored.
There is no general consensus on how to proceed after 
birth in pregnancies with euploid fetuses without obvious 
structural anomalies. The minimum requirement is clinical 
examination of the neonate. Since it is generally accepted that 
long-term neurological outcome is favorable in such cases, 
there is no need for special follow-up.
Singleton pregnancy
No obvious lethal/major anomaly
Invasive procedure
(CVS, AFS, storage of cultured cells)
Microarray (?)
Normal cytogenetics
18–22 gestational weeks
3rd level US and fetal echocardiography
Normal 2nd  trimester
sonogram
Dichorionic twin
pregnancy
Monochorionic diamniotic
twin pregnancy
Abnormal cytogenetics
TOP
MFPR
Cord coagulation
IUFD
Major anomaly
TTTS
Postnatal clinical
examination
Multidisciplinary counseling
in utero treatment
pregnancy follow-up
Postnatal treatment
Screening for TTTS 
Postmortem detailed
examination of fetus and placenta
Figure 1 A protocol of management of pregnancies with increased fetal nuchal translucency on singleton, monochorionic and dichorionic twin pregnancies.
Abbreviations: CvS, chorionic villus sampling; AFS, amniotic fluid sampling; TTTS, twin-to-twin transfusion syndrome; TOP, termination of pregnancy; MFPR, multifetal 
pregnancy reduction; iUFD, intrauterine fetal death; US, ultrasound.
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A protocol of management of pregnancies with increased 
fetal NT on singleton, monochorionic, and dichorionic twin 
pregnancies is shown in Figure 1.
Antenatal counseling and  
patients’ awareness
Apart from the tremendous possibilities highly valued by 
pregnant women, prenatal screening carries also limitations, 
ethical issues, and potentially difficult decisions. There 
is generally accepted consensus that participation in the 
prenatal screening should be based on informed consent.50 
Providing professional and comprehensive information 
on prenatal examinations is challenging and often remains 
inadequate. Unfortunately, prenatal screening decisions 
are often not informed decisions. This is inconsistent with 
the main objective of offering screening which is to enable 
individuals to make informed decisions.51 Ethical issues, 
educational level, and language barriers should also be taken 
into consideration.52
Regarding NT screening, there should be three levels 
of counseling: 1) pre-screening (informed decision about 
the screening based on the health provider’s information 
about the benefits and possible harms of screening regard-
ing  false-positive results); 2) counseling after increased 
NT detection (invasive procedures and related risk, 
“residual” risk of major structural anomaly in euploid 
fetuses); 3) counseling after detection of aneuploidy or 
major structural anomaly since the outcome greatly varies 
among various aneuploidies and structural anomalies. A 
multidisciplinary expert team should be involved in such 
cases with additional individual psychological support to 
the parents.
Conclusion
NT screening is the powerful tool in modern obstetrical 
practice which enables increased detection of aneuploidies 
and major structural anomalies and ultimately leads to  better 
quality of obstetric care. Significance of NT screening for 
detection of SGS and prediction of TTTS in monochori-
onic twin pregnancies is still disputable. The long-term 
neurological outcome of euploid children without structural 
anomalies after increased fetal NT seems to be favorable. 
Quality of NT screening should be high. Counseling should 
be improved due to the high level of anxiety and emotional 
impact linked to NT screening.
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